Biblio

Export 3166 results:
Author Title [ Type(Desc)] Year
Journal Article
I. A. C. Arnoldussen, Sundh, V., Bäckman, K., Kern, S., Östling, S., Blennow, K., Zetterberg, H., Skoog, I., Kiliaan, A. J., and Gustafson, D. R., “A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1325-1335, 2018.
L. Wu, Liu, J., Feng, X., Dong, J., Qin, W., Liu, Y., Wang, J., Lu, J., Chen, K., Wang, Y., and Jia, J., “11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.”, J Alzheimers Dis, vol. 61, no. 2, pp. 613-618, 2018.
H. Jin Kim, Cho, H., Werring, D. J., Jang, Y. Kyoung, Kim, Y. Jin, San Lee, J., Lee, J., Jun, S., Park, S., Ryu, Y. Hoon, Choi, J. Yong, Cho, Y. Seok, Moon, S. Hwan, Na, D. L., Lyoo, C. Hyoung, and Seo, S. Won, “18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 57, no. 3, pp. 711-716, 2017.
M. Khosravi, Peter, J., Wintering, N. A., Serruya, M., Shamchi, S. Pourhassan, Werner, T. J., Alavi, A., and Newberg, A. B., “18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.”, J Alzheimers Dis, vol. 70, no. 4, pp. 1197-1207, 2019.
N. Smailagic, Lafortune, L., Kelly, S., Hyde, C., and Brayne, C., “18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1175-1194, 2018.
C. M. Lee, Jacobs, H. I. L., Marquié, M., Becker, J. A., Andrea, N. V., Jin, D. S., Schultz, A. P., Frosch, M. P., Gómez-Isla, T., Sperling, R. A., and Johnson, K. A., “18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1691-1702, 2018.
L. Flem Kalheim, Fladby, T., Coello, C., Bjørnerud, A., and Selnes, P., “[18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1595-1607, 2018.
M. T. Fodero-Tavoletti, Okamura, N., Furumoto, S., Mulligan, R. S., Connor, A. R., McLean, C. A., Cao, D., Rigopoulos, A., Cartwright, G. A., O'Keefe, G., Gong, S., Adlard, P. A., Barnham, K. J., Rowe, C. C., Masters, C. L., Kudo, Y., Cappai, R., Yanai, K., and Villemagne, V. L., “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
H. - L. Gao, Li, C., Nabeka, H., Shimokawa, T., Wang, Z. - Y., Cao, Y. - M., and Matsuda, S., “An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of Aβ1-42 Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice.”, J Alzheimers Dis, vol. 53, no. 3, pp. 1173-92, 2016.
J. Jia, Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., and Jia, L., “A 19-Year-Old Adolescent with Probable Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
A. A. Sepehry, Lee, P. E., Hsiung, G. - Y. R., B Beattie, L., Feldman, H. H., and Jacova, C., “The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.”, J Alzheimers Dis, vol. 58, no. 2, pp. 449-462, 2017.
S. M. de la Monte, Tong, M., and Wands, J. R., “The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1381-1390, 2018.
M. Heath, Shellington, E., Titheridge, S., Gill, D. P., and Petrella, R. J., “A 24-Week Multi-Modality Exercise Program Improves Executive Control in Older Adults with a Self-Reported Cognitive Complaint: Evidence from the Antisaccade Task.”, J Alzheimers Dis, vol. 56, no. 1, pp. 167-183, 2017.
X. - Y. He, Dobkin, C., W Brown, T., and Yang, S. - Y., “3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1487-1497, 2022.
C. - A. Castellano, Paquet, N., Dionne, I. J., Imbeault, H., Langlois, F., Croteau, E., Tremblay, S., Fortier, M., J Matte, J., Lacombe, G., Fülöp, T., Bocti, C., and Cunnane, S. C., “A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer's Disease: Preliminary Results from a Neuroimaging Study.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1459-1468, 2017.
T. Tian, Qin, X., Wang, Y., Shi, Y., and Yang, X., “40 Hz Light Flicker Promotes Learning and Memory via Long Term Depression in Wild-Type Mice.”, J Alzheimers Dis, vol. 84, no. 3, pp. 983-993, 2021.
L. Chen, Shen, Q., Xu, S., Yu, H., Pei, S., Zhang, Y., He, X., Wang, Q. Z., and Li, D., “5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 573-585, 2022.
R. Guo, Fan, G., Zhang, J., Wu, C., Du, Y., Ye, H., Li, Z., Wang, L., Zhang, Z., Zhang, L., Zhao, Y., and Lu, Z., “A 9-microRNA Signature in Serum Serves as a Noninvasive Biomarker in Early Diagnosis of Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1365-1377, 2017.
C. D. Pereira, Martins, F., Wiltfang, J., Silva, O. A. B. da Cru, and Rebelo, S., “ABC Transporters Are Key Players in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 463-485, 2018.
A. Boehm-Cagan, Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., and Michaelson, D. M., “ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.”, J Alzheimers Dis, vol. 54, no. 3, pp. 1219-1233, 2016.
N. F. Fitz, Carter, A. Y., Tapias, V., Castranio, E. L., Kodali, R., Lefterov, I., and Koldamova, R., “ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice.”, J Alzheimers Dis, vol. 56, no. 3, pp. 1075-1085, 2017.
Y. Lamartinière, Boucau, M. - C., Dehouck, L., Krohn, M., Pahnke, J., Candela, P., Gosselet, F., and Fenart, L., “ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid-β Peptide Efflux in an in vitro Model of the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1195-1211, 2018.
N. Sinha, Berg, C. N., Shaw, A., and Gluck, M. A., “ABCA7 Genotype Moderates the Effect of Aerobic Exercise Intervention on Generalization of Prior Learning in Healthy Older African Americans.”, J Alzheimers Dis, vol. 74, no. 1, pp. 309-318, 2020.
Q. - F. Zhao, Wan, Y., Wang, H. - F., Sun, F. - R., Hao, X. - K., Tan, M. - S., Tan, C. - C., Zhang, D. - Q., Tan, L., and Yu, J. - T., “ABCA7 Genotypes Confer Alzheimer's Disease Risk by Modulating Amyloid-β Pathology.”, J Alzheimers Dis, vol. 52, no. 2, pp. 693-703, 2016.
Y. H. Fu, Hsiao, J. - H. T., Paxinos, G., Halliday, G. M., and Kim, W. Scott, “ABCA7 Mediates Phagocytic Clearance of Amyloid-β in the Brain.”, J Alzheimers Dis, vol. 54, no. 2, pp. 569-84, 2016.

Pages